GlobeNewsWire
14 Jul 2026, 06:30 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
PMN310 demonstrated a dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid during a Phase 1a trial. — This provides critical first-in-human proof of target engagement, reducing the technical risk for the lead drug candidate.
+0.60ProMIS Neurosciences expects to present blinded six-month interim data from its Phase 1b PRECISE-AD trial in the coming weeks. — Near-term catalyst that will provide the first safety and biomarker trends in actual Alzheimer's patients.
+0.40PMN310 is designed to target toxic oligomers while avoiding amyloid plaques, potentially reducing the risk of ARIA side effects. — If proven, this differentiates the drug from existing plaque-binding therapies by offering a superior safety profile.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company reported successful first human evidence of target engagement for its lead Alzheimer's drug candidate PMN310.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
1d ago
